Verrica Pharmaceuticals receives $8M trigger payment from Japanese product development partner


The payment was triggered by the start of a Phase 3 clinical trial for a new drug candidate.

Previous CVS, off a strong Q2, still plans to enter primary care space in 2022
Next Moderna aiming to deliver updated Covid-19 vaccine boosters next month